Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells

Cancer Research

Volumn 76, Issue 19, 2016, Pages 5756-5767

  Tsai, Chin Hsien ^a,b   Tzeng, Sheue Fen ^a,c   Chao, Tai Kuang ^d   Tsai, Chia Yun ^a   Yang, Yu Chih ^a   Lee, Ming Ting ^b   Hwang, Jiuan Jiuan ^e   Chou, Yu Ching ^c   Tsai, Mong Hsun ^a,b   Cha, Tai Lung ^c,d   Hsiao, Pei Wen ^a,c  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; GALECTIN 4; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; C1GALT1 PROTEIN, HUMAN; GALACTOSYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; POLYSACCHARIDE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BIOSYNTHESIS; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RECEPTOR BINDING; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GALACTOSYLTRANSFERASES; GALECTIN 4; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; POLYSACCHARIDES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84989888984     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0641     Document Type: Article

References (31)

1. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28.
2. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29.
3. Behnsawy HM, Miyake H, Harada K, Fujisawa M. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int 2013;111:30-7.
4. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42.
5. Brockhausen I.Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006;7:599-604.
6. Huflejt ME, Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J 2004;20:247-55.
7. Stowell SR, Arthur CM, Dias-Baruffi M, Rodrigues LC, Gourdine JP, Heimburg-Molinaro J, et al. Innate immune lectins kill bacteria expressing blood group antigen. Nat Med 2010;16:295-301.
8. Hughes RC. Secretion of the galectin family of mammalian carbohydratebinding proteins. Biochim Biophys Acta 1999;1473:172-85.
9. Huflejt ME, Jordan ET, Gitt MA, Barondes SH, Leffler H. Strikingly different localization of galectin-3 and galectin-4 in human colon adenocarcinoma T84 cells. Galectin-4 is localized at sites of cell adhesion. J Biol Chem 1997;272:14294-303.
10. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001; 61:889-95.
11. Hayashi T, Saito T, Fujimura T, Hara K, Takamochi K, Mitani K, et al. Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma. PLoS One 2013;8:e81883.
12. Cai Z, Zeng Y, Xu B, Gao Y, Wang S, Zeng J, et al. Galectin-4 serves as a prognostic biomarker for the early recurrence /metastasis of hepatocellular carcinoma. Cancer Sci 2014;105:1510-7.
13. Satelli A, Rao PS, Thirumala S, Rao US. Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer 2011;129:799-809.
14. Tsai CH, Teng CH, Tu YT, Cheng TS, Wu SR, Ko CJ, et al. HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. Oncogene 2014;33:4643-52.
15. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
16. Hauselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol 2014;4:28.
17. Tsuboi S, Hatakeyama S, Ohyama C, Fukuda M. Two opposing roles of Oglycans in tumor metastasis. Trends Mol Med 2012;18:224-32.
18. Lee SH, Hatakeyama S, Yu SY, Bao X, Ohyama C, Khoo KH, et al. Core3 Oglycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. J Biol Chem 2009;284:17157-69.
19. Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH, Hu RH, et al. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res 2013;73:5580-90.
20. Hung JS, Huang J, Lin YC, Huang MJ, Lee PH, Lai HS, et al. C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2. Oncotarget 2014;5: 2096-106.
21. Petrosyan A, Holzapfel MS, Muirhead DE, Cheng PW. Restoration of compact Golgi morphology in advanced prostate cancer enhances susceptibility to galectin-1-induced apoptosis by modifying mucin O-glycan synthesis. Mol Cancer Res 2014;12:1704-16.
22. Reticker-Flynn NE, Bhatia SN. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov 2015;5:168-81.
23. Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 2011;17:7035-46.
24. Liu W, Hsu DK, Chen HY, Yang RY, Carraway KLIII, Isseroff RR, et al. Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration. J Invest Dermatol 2012;132:2828-37.
25. Lin MC, Huang MJ, Liu CH, Yang TL, Huang MC. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity. Oral Oncol 2014;50:478-84.
26. Ho WL, Chou CH, Jeng YM, Lu MY, Yang YL, Jou ST, et al. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma. Oncotarget 2014;5:12247-59.
27. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 2010;33:609-13.
28. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014;156:744-58.
29. Xu C, Ng DT. Glycosylation-directed quality control of protein folding. Nat Rev Mol Cell Biol 2015;16:742-52.
30. Tan FY, Tang CM, Exley RM. Sugar coating: bacterial protein glycosylation and host-microbe interactions. Trends Biochem Sci 2015;40:342-50.
31. Pan Y, Yago T, Fu J, Herzog B, McDaniel JM, Mehta-D'Souza P, et al. Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets. Blood 2014;124: 3656-65.